JP2024519195A5 - - Google Patents
Info
- Publication number
- JP2024519195A5 JP2024519195A5 JP2023564484A JP2023564484A JP2024519195A5 JP 2024519195 A5 JP2024519195 A5 JP 2024519195A5 JP 2023564484 A JP2023564484 A JP 2023564484A JP 2023564484 A JP2023564484 A JP 2023564484A JP 2024519195 A5 JP2024519195 A5 JP 2024519195A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- galectin
- particle according
- antigen
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178755P | 2021-04-23 | 2021-04-23 | |
| US63/178,755 | 2021-04-23 | ||
| PCT/JP2022/018610 WO2022225057A1 (en) | 2021-04-23 | 2022-04-22 | Galectin-targeting immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024519195A JP2024519195A (ja) | 2024-05-09 |
| JP2024519195A5 true JP2024519195A5 (enExample) | 2025-04-21 |
Family
ID=83723024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564484A Pending JP2024519195A (ja) | 2021-04-23 | 2022-04-22 | ガレクチン標的の免疫療法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12636341B2 (enExample) |
| EP (1) | EP4326858A4 (enExample) |
| JP (1) | JP2024519195A (enExample) |
| CN (1) | CN117222734A (enExample) |
| WO (1) | WO2022225057A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025513920A (ja) * | 2022-04-18 | 2025-04-30 | Ｃｙｎ－Ｋバイオ株式会社 | 炎症性疾患の処置 |
| WO2025084276A1 (ja) | 2023-10-16 | 2025-04-24 | Ｃｙｎ－Ｋバイオ株式会社 | 肥満の処置 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6753314B1 (en) * | 1999-04-01 | 2004-06-22 | Curagen Corporation | Protein-protein complexes and methods of using same |
| WO2003068804A2 (en) | 2002-02-14 | 2003-08-21 | Novavax, Inc. | Novel insect cell line |
| US20040023855A1 (en) | 2002-04-08 | 2004-02-05 | John Constance M. | Biologic modulations with nanoparticles |
| CN102317308A (zh) * | 2008-11-26 | 2012-01-11 | 美国国有健康与人类服务部 | 类病毒组合物颗粒及其使用方法 |
| WO2012106356A2 (en) | 2011-01-31 | 2012-08-09 | GOVERNMENT OF THE USA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES | Virus-like particles and methods of use |
| MX357202B (es) | 2012-02-16 | 2018-06-28 | Vlp Therapeutics Llc | Composicion de particula tipo virus. |
| SG11201509614SA (en) | 2013-06-03 | 2015-12-30 | Vlp Therapeutics Llc | Malaria vaccine |
| TWI720946B (zh) | 2014-08-08 | 2021-03-11 | 美商Ｖｌｐ醫療股份有限公司 | 包含改質套膜蛋白質ｅ３之類病毒粒子 |
| GB201512369D0 (en) | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| SE1500434A1 (en) * | 2015-10-29 | 2017-04-30 | Theravac Pharmaceuticals Ab | A novel fusion partner for highly efficient and safe vaccines |
| CN109562153A (zh) * | 2016-08-07 | 2019-04-02 | 诺华股份有限公司 | mRNA介导的免疫方法 |
| AU2018212584B2 (en) * | 2017-01-27 | 2020-12-10 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| WO2018138257A1 (en) * | 2017-01-27 | 2018-08-02 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| WO2019075062A1 (en) * | 2017-10-11 | 2019-04-18 | University Of Florida Research Foundation | MODIFIED GAL-1 PROTEINS AND USES THEREOF |
| JP2021501180A (ja) | 2017-10-31 | 2021-01-14 | ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＧａｌｅｃｔｉｎ Ｓｃｉｅｎｃｅｓ， ＬＬＣ | 全身インスリン抵抗性障害の治療のためのセレノガラクトシド化合物およびその使用 |
| WO2024143497A1 (ja) | 2022-12-28 | 2024-07-04 | 国立大学法人京都大学 | Ｃｄ１５３を標的とする医薬組成物 |
-
2022
- 2022-04-22 EP EP22791828.1A patent/EP4326858A4/en active Pending
- 2022-04-22 JP JP2023564484A patent/JP2024519195A/ja active Pending
- 2022-04-22 CN CN202280030030.XA patent/CN117222734A/zh active Pending
- 2022-04-22 US US17/726,623 patent/US12636341B2/en active Active
- 2022-04-22 WO PCT/JP2022/018610 patent/WO2022225057A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106471125B (zh) | 包括白蛋白结合部分的腺病毒 | |
| EP3292142B1 (en) | Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment | |
| JP2022163182A5 (enExample) | ||
| CN113817029B (zh) | 一种新型冠状病毒s-rbd三聚体蛋白疫苗、其制备方法和应用 | |
| CA2680659C (en) | Adenovirus with mutations in the endoplasmic reticulum retention domain of the e3-19k protein and their use in cancer treatment | |
| JP2022051775A5 (enExample) | ||
| US10435712B2 (en) | Evolution of high-titer virus-like vesicles for vaccine applications | |
| JP2020511165A (ja) | プログラム可能な腫瘍溶解性ウイルスワクチン系及びその適用 | |
| HU230364B1 (hu) | Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására | |
| JP2008533988A5 (enExample) | ||
| JP2024180560A5 (enExample) | ||
| US20230203137A1 (en) | Preparation method of artificial antibody | |
| JP2019527036A (ja) | 改変糖タンパク質ｄを有するヘルペスウイルス | |
| JP2026500600A (ja) | Ｈｐｖ感染関連疾患を予防又は治療するためのポリヌクレオチド分子 | |
| JP2023522154A5 (enExample) | ||
| EP4717766A1 (en) | Dendritic cell-targeted viroid dvlp, and preparation method therefor and use thereof | |
| JP2018533908A (ja) | 標的ポリペプチドを提示するためのポリペプチド担体及びその使用 | |
| JP2020526202A5 (enExample) | ||
| JP2024523329A5 (enExample) | ||
| JP2025513920A5 (enExample) | ||
| WO2003006654A2 (en) | Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom | |
| CN118703545A (zh) | 一种促进iNKT细胞精准再识别iNKT免疫逃逸型胰腺癌肿瘤细胞亚群的基因线路 | |
| CN100462438C (zh) | 用于防御人体免疫缺陷病毒感染的嵌合的5型/11型或5型/35型腺病毒载体 | |
| CN121319150B (zh) | 一种同时识别hbv核心抗原表位及包膜蛋白表位的tcr及其编码序列 | |
| JP2006515172A (ja) | パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物 |